Dual targeting of endothelial cells and pericytes in antivascular therapy for ovarian carcinoma

Chunhua Lu, Aparna A. Kamat, Yvonne G. Lin, William M. Merritt, Charles N. Landen, Jin Kim Tae, Whitney Spannuth, Thiru Arumugam, Liz Y. Han, Nicholas B. Jennings, Craig Logsdon, Robert B. Jaffe, Robert L. Coleman, Anil K. Sood

Research output: Contribution to journalArticlepeer-review

74 Scopus citations


Purpose: Pericytes are known to provide a survival advantage for endothelial cells. We hypothesize that strategies aimed at dual targeting of tumor-associated endothelial cells and pericytes will be highly efficacious. Experimental Design: Paclitaxel-sensitive (HeyA8 and SKOV3ip1) or paclitaxel-resistant (HeyA8-MDR) orthotopic tumors in mice were examined for therapeutic efficacy by targeting the endothelial cells (using a vascular endothelial growth factor receptor inhibitor, AEE788) and pericytes (using STI571) alone or in combination. Additional therapy and survival studies in combination with paclitaxel were also done. Following therapy, tumors were examined for endothelial cell apoptosis, pericyte coverage, microvessel density, and proliferation. Results: AEE788 inhibited tumor growth by 45% and 59% in the HeyA8 and SKOV3ip1 models, respectively, whereas STI571 alone was not effective. AEE788 plus STI571 resulted in 69% to 84% inhibition of tumor growth in both models. Moreover, combination of these agents with paclitaxel was even more effective, resulting in up to 98% inhibition of tumor growth. The triple combination was even effective in the HeyA8-MDR model. Remarkably, this triple combination also resulted in improved survival compared with all other groups (P < 0.001) and caused regression of formed tumors. Pericyte coverage was significantly decreased in the STI571 treatment groups, and microvessel density was significantly reduced in the AEE788 treatment groups. AEE788 induced endothelial cell apoptosis, which was further enhanced by the addition of STI571. Conclusions: Strategies targeting both endothelial cells and pericytes are highly effective for in vivo treatment of ovarian carcinoma. This antiangiogenic effect may be partially due to decreased pericyte coverage, thus increasing the sensitivity of tumor vasculature to therapy. These encouraging data support the development of clinical trials based on this strategy.

Original languageEnglish (US)
Pages (from-to)4209-4217
Number of pages9
JournalClinical Cancer Research
Issue number14
StatePublished - Jul 15 2007

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Dual targeting of endothelial cells and pericytes in antivascular therapy for ovarian carcinoma'. Together they form a unique fingerprint.

Cite this